Results 11 to 20 of about 103,766,681 (205)

Characteristics, Immunological Response & Treatment Outcomes of HIV-2 Compared with HIV-1 & Dual Infections (HIV 1/2) in Mumbai [PDF]

open access: yes, 2010
Information available on HIV-2 and dual infection (HIV-1/2) is limited. This study was carried out among HIV positive individuals in an urban referral clinic in Khar, Mumbai, India, to report on relative proportions of HIV-1, HIV-2 and HIV-1/2 and ...
Manzi, M   +9 more
core   +6 more sources

An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates. [PDF]

open access: yesInt J Mol Sci, 2023
Funding Information: This work was funded by national funds through the FCT-Foundation for Science and Technology, I.P., under the project UIDB/04585/2020, by FCT and Aga Khan Development Network (AKDN)—Portugal Collaborative Research Network in ...
Taveira N   +8 more
europepmc   +2 more sources

Modulation of transferrin receptor by HIV-2. [PDF]

open access: yesVirol J
Abstract Human immunodeficiency viruses (HIV-1 and HIV-2), are the causative agents of the acquired immunodeficiency syndrome (AIDS), that share substantial genomic and structural similarities, yet differ in replication dynamics and disease progression.
Al-Muffti AS   +3 more
europepmc   +3 more sources

Korespondensi Jurnal HIV Nursing: Bibliometric analysis on policy strategies regarding HIV/AIDS [PDF]

open access: yes, 2023
The Covid-19 pandemic that has hit the world of health in the last 2-3 years has been given more significant impact on people living with HIV/AIDS globally.
Umam, Khaerul
core   +1 more source

The LEDGIN GS-9822 inhibits HIV-2 infection and enhances HIV-2 latency. [PDF]

open access: yesMicrobiol Spectr
ABSTRACT HIV integration is targeted toward active transcription units through the interaction of HIV integrase with the cellular co-factor LEDGF/p75. LEDGINs, small molecule inhibitors of this interaction, reduce HIV-1 integration and retarget residual proviruses away from active ...
Bruggemans A   +5 more
europepmc   +4 more sources

PANGEA-HIV/PANGEA-Sequences: v1.0.0

open access: yes, 2023
<h2><a href="https://github.com/pangea-hiv/#hiv-consensus-sequence-repository-of-the-pangea-hiv-consortium">HIV Consensus Sequence Repository</a><br><a href="https://github.com/pangea-hiv/#hiv-consensus-sequence-repository-of ...
PANGEA-HIV Consortium
core   +1 more source

The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. [PDF]

open access: yes, 2001
OBJECTIVES: To estimate age- and sex-specific herpes simplex virus type-2 (HSV-2) prevalence in urban African adult populations and to identify factors associated with infection. DESIGN AND METHODS: Cross-sectional, population-based samples of about 2000
Robinson, NJ   +24 more
core   +1 more source

Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania. [PDF]

open access: yes, 2013
To compare the presence and quantity of cervicovaginal HIV among HIV seropositive women with clinical herpes, subclinical HSV-2 infection and without HSV-2 infection respectively; to evaluate the association between cervicovaginal HIV and HSV shedding ...
Riedner, Gabriele   +32 more
core   +1 more source

Leishmaniasis in HIV-infected patients: difficulties in diagnostics and treatment

open access: yesЛечащий Врач, 2022
In this article, leishmaniasis is considered in the context of HIV infection, in which this disease appears to be an opportunistic. A general characteristic  of leishmaniasis is given, and the features of the course of infection in immunodeficiency are ...
M. V. Nagibina   +7 more
doaj   +1 more source

Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus

open access: yesViruses, 2016
Pseudovirion-based neutralization assay is considered the gold standard method for evaluating the immune response to human papillomavirus (HPV) vaccines.
Jianhui Nie   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy